Calcium alpha-ketoglutarate and biological aging: what the evidence actually shows

What Ca-AKG actually is

Alpha-ketoglutarate — abbreviated AKG, and sometimes written α-KG — is not an exotic compound. It is a molecule your own cells make constantly, a central intermediate in the tricarboxylic acid (TCA) cycle, the chemical loop inside your mitochondria that turns food into usable energy. (The TCA cycle is also called the Krebs cycle or citric-acid cycle; same thing.) AKG is one of the busiest crossroads in that loop: it links carbohydrate, fat, and amino-acid metabolism, acts as a nitrogen scavenger, and serves as a precursor to glutamate and glutamine [5].

“Calcium alpha-ketoglutarate,” or Ca-AKG, is just AKG paired with calcium to make a stable, swallowable salt — the same trick used to turn many reactive metabolites into shelf-stable supplements. That detail matters more than it sounds, and we’ll come back to it: every gram of the calcium salt also delivers calcium, which is not a free ingredient for everyone. The interest in AKG for aging comes from two separate observations — that AKG levels decline as organisms get older, and that AKG sits on enzymes directly involved in maintaining a youthful epigenome. To see why that’s intriguing, you have to look at what the molecule does.

The mechanism: energy metabolite and epigenetic cofactor

AKG wears two hats. The first is metabolic: as a TCA-cycle intermediate it helps govern the overall rate of cellular energy production, and its levels shift with fasting, exercise, and age [5]. In the worm Caenorhabditis elegans, AKG was shown to extend lifespan by inhibiting ATP synthase and dialing down TOR signaling — the same nutrient-sensing pathway that fasting and rapamycin act on [5]. That places AKG, mechanistically, in the neighborhood of the best-studied longevity levers we have.

The second hat is epigenetic, and it is the more provocative one. A large family of enzymes — the α-ketoglutarate-dependent dioxygenases — literally cannot function without AKG as a cofactor. Among them are the TET (ten-eleven translocation) enzymes, which drive DNA demethylation by oxidizing methylated cytosine, and the Jumonji-family histone demethylases [7]. In plain terms: AKG is one of the raw materials your cells use to add and remove the chemical marks that decide which genes are switched on. When AKG (or the related cofactor vitamin C) runs low, TET activity falls and the demethylation machinery slows, shifting methylation patterns [7][8]. Because the most widely used “aging clocks” read out exactly these DNA-methylation marks, a molecule that fuels the demethylation enzymes is a plausible — though not proven — lever on those clocks.

Two honest caveats sit inside that mechanism. First, the relationship is not a simple dial: when researchers treated human cells with succinate (which competes with AKG at these same enzymes), they expected sweeping methylation changes and found surprisingly few genome-wide shifts [6] — a reminder that cofactor supply is one input among many, not a master switch. Second, “plausible mechanism” is where most failed supplements also start. A clean story about how something could work is a reason to run the experiment, not evidence that it does.

The strong part: the mouse data

The study that put Ca-AKG on the longevity map is Asadi Shahmirzadi and colleagues, published in Cell Metabolism in 2020 [1]. The team at the Buck Institute fed calcium-AKG (CaAKG) to aging C57BL/6 mice and ran a battery of longitudinal, clinically relevant measurements rather than just counting deaths. Two findings stood out. CaAKG extended lifespan — modestly but reproducibly — and, more importantly, it compressed morbidity: the mice spent a smaller fraction of their lives frail and sick. By standardized frailty scoring, the treated animals were measurably healthier in old age, not merely longer-lived [1].

The proposed mechanism made the result more credible rather than less. The benefit tracked with a drop in systemic inflammatory cytokines, and the authors traced it to induction of IL-10, an anti-inflammatory signal, suggesting AKG suppresses the chronic, smoldering inflammation (“inflammaging”) that drives much of late-life decline [1]. That is a coherent, mechanism-anchored story in a rigorous animal model — genuinely strong preclinical evidence.

But read the species line carefully. This is a mouse study. The lifespan and frailty results are in C57BL/6 mice, fed AKG in their diet, in a controlled lab. The history of geroscience is a graveyard of compounds that extended life in mice or worms and did nothing measurable in people. Strong preclinical data earns a compound a serious human trial. It does not, by itself, earn it a place in your medicine cabinet.

The fragile part: the human pilot

Here is the number everyone repeats. In 2021, Demidenko and colleagues published a study in the journal Aging reporting that people taking Rejuvant® — an alpha-ketoglutarate-based formulation that also contains vitamins — showed an average decrease in biological aging of about 8 years, measured by the TruAge DNA-methylation test, after an average of roughly 7 months of use [2]. Taken at face value, that is one of the largest age-reversal signals ever reported for an oral supplement. So why does this article keep flagging it?

Because of how the study was built. It was a retrospective, open-label analysis of 42 individuals — a small open-label cohort, n=42, with no control arm and no placebo [2]. The authors themselves are explicit that “continued testing, particularly in a placebo-controlled design, is required” [2]. Sit with what “no control” means here. There was no comparison group of similar people not taking the supplement. Everyone in the analysis was already buying and taking Rejuvant — a self-selected, health-motivated group. The participants knew what they were taking, knew it was marketed as an anti-aging product, and were likely improving diet, sleep, and exercise in parallel. Epigenetic clocks also carry real measurement noise and can drift with a single blood draw, time of day, or cell-composition shift. With no placebo group, there is no way to separate a true drug effect from regression to the mean, lifestyle confounding, expectation effects, and clock variability. The honest reading is not “Ca-AKG turns back your clock 8 years.” It is: “a small uncontrolled pilot generated a striking hypothesis that a real trial now has to test.”

That framing isn’t hostile to AKG — it’s the same framing the field uses. A 2022 review in Aging Cell surveyed which interventions appear to move human aging clocks and named alpha-ketoglutarate among the molecules associated with reduced epigenetic age, while stressing that “rigorous clinical trials are needed to validate these initial findings” and that the clinical meaning of nudging a clock’s output is still unsettled [4]. The reassuring part of the story is that the trial AKG needs is actually happening: the ABLE study (Alpha-ketoglutarate Supplementation and BiologicaL agE) is a double-blind, placebo-controlled randomized trial of 1 g sustained-release calcium-AKG versus placebo over six months in 120 middle-aged adults whose biological age exceeds their chronological age [3]. As of its 2025 recruitment report it had successfully enrolled its cohort [3]. Until that data lands, the human case for Ca-AKG rests on one uncontrolled pilot — and a single uncontrolled study is the thinnest possible foundation for a confident claim.

The mouse data is strong and the human pilot is intriguing — but “an 8-year drop in an uncontrolled cohort of 42 people” is a hypothesis to test, not a result to bank.

Evidence Radar: how we grade it

On the Wellness Radar scale, where 5 is “proven in humans by replicated randomized trials with hard outcomes” and 1 is “hype with no credible support,” Ca-AKG splits across two different claims:

• Healthspan / frailty in mice — grade 4 (preclinical, strong): a rigorous, mechanism-anchored animal study in Cell Metabolism [1]. Strong, but it is an animal grade, not a human one.
• Reduces human biological (epigenetic) age — grade 3, EMERGING: one striking but small, open-label, uncontrolled pilot [2], a candidate flagged in a review [4], and a placebo-controlled trial still in progress [3]. Promising; not established.
• Extends human lifespan or prevents disease — grade 2, unproven: there is no human lifespan or hard-outcome data at all. The lifespan evidence is in mice [1] and worms [5].

The single most important thing to carry away: the part of the Ca-AKG story that is strong (mouse healthspan) is not the part being sold to you (human age reversal), and the part being sold to you is the part resting on the weakest design.

A tiered way to think about it

We don’t publish doses, and we’re not going to start here — this is emerging evidence, and prescriptive numbers would overstate what we know. Instead, a tiered way to locate yourself honestly:

Foundational tier. If your goal is to age well and you’re not already doing the boring, proven things — resistance training, adequate protein, sleep, not smoking, managing blood pressure and glucose — that is where the largest, best-evidenced longevity returns live. AKG is a rounding error next to any of them. No supplement earns a place above this tier.

Research-curious tier. If your fundamentals are genuinely handled and you follow geroscience closely, Ca-AKG is a reasonable thing to watch: the mechanism is real, the mouse data is clean, and a proper human trial is underway [3]. Watching the ABLE result before acting is, frankly, the more rigorous move than pre-empting it.

Experimental tier. Some longevity-focused adults already take Ca-AKG, often stacked with NAD⁺ precursors, spermidine, or rapamycin. If you’re in this group, treat it as an experiment on yourself with incomplete data: do it under clinician supervision, account for the calcium load in your total daily intake, and don’t mistake an epigenetic-clock reading for proof it’s working — those clocks are noisy enough that a single hopeful number means little.

Grey areas and open questions

The open-label hype loop. The 8-year figure has been repeated so often it has hardened into folk-fact, detached from its caveats. Every time it appears without “open-label, n=42, no control,” it overstates the evidence. The number isn’t fabricated — it’s just been stripped of the design that determines what it’s worth.

The formulation question. The human pilot tested Rejuvant specifically — AKG plus added vitamins [2], not pure AKG. Vitamin C is itself a cofactor for the same TET demethylation enzymes [7][8], so any effect could owe something to the co-ingredients, not the AKG alone. “The study showed Rejuvant did X” is not the same sentence as “AKG does X.”

Supplement-grade variability. AKG sold as a supplement isn’t a regulated drug. Salt form, dose, sustained-release versus immediate, and purity vary across products, and a label number is not a guarantee of what’s in the capsule. The ABLE trial deliberately specifies a sustained-release 1 g calcium-AKG [3]; an off-the-shelf product may not match it.

The calcium load. This is the practical risk people skip. Because it’s a calcium salt, Ca-AKG delivers calcium with every dose — relevant for anyone already supplementing calcium, prone to kidney stones, with kidney disease, or on medications affected by calcium. Calcium is a real variable in vascular and stone risk, not an inert filler. AKG also turns up in human bone and mineral-metabolism studies [9], which is interesting but does not establish a benefit. Total daily calcium is a number to actually add up.

The biggest open question: there is still no completed randomized, placebo-controlled human trial, and no human hard-outcome data — no demonstrated effect on disease, disability, or mortality in people. An epigenetic clock is a proxy, and even moving a proxy doesn’t guarantee you’ve moved the thing that matters [4]. That is the gap between “emerging” and “proven,” and it is the whole reason for the cautious grade.

What this article is not saying

This is not “Ca-AKG is proven to reverse aging.” It is not. The strong evidence is in mice [1], the standout human number comes from a single small uncontrolled pilot [2], and the trial that could actually establish a human effect is still running [3].

This is also not “Ca-AKG is snake oil.” That would be just as dishonest in the other direction. The mechanism is real and well-characterized [5][7], the preclinical data is rigorous [1], and a serious research group thought the signal strong enough to fund a randomized trial [3]. This is a legitimately interesting compound at an early stage — which is a more uncomfortable, and more accurate, place than either headline.

And this is not a recommendation to take it. Whether any longevity supplement belongs in your routine — alongside your calcium intake, medications, kidney health, and actual goals — is a clinical decision to make with a qualified clinician, ideally one who will tell you, before anything else, that training, protein, and sleep will out-perform every capsule in this category. The point of this piece is to hand you the evidence at its true strength, so that conversation can be an honest one.